30157683|t|Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts.
30157683|a|AIM: ERC1671 is an allogeneic/autologous therapeutic glioblastoma (GBM) vaccine - composed of whole, inactivated tumor cells mixed with tumor cell lysates derived from the patient and three GBM donors. METHODS: In this double-blinded, randomized, Phase II study bevacizumab-naive patients with recurrent GBM were randomized to receive either ERC1671 in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) (Leukine  or sargramostim) and cyclophosphamide plus bevacizumab, or placebo plus bevacizumab. Interim results: Median overall survival (OS) of patients treated with ERC1671 plus bevacizumab was 12 months. In the placebo plus bevacizumab group, median OS was 7.5 months. The maximal CD4+ T-lymphocyte count correlated with OS in the ERC1671 but not in the placebo group. CONCLUSION: The addition of ERC1671/GM-CSF/cyclophosphamide to bevacizumab resulted in a clinically meaningful survival benefit with minimal additional toxicity.
30157683	18	25	ERC1671	Chemical	-
30157683	31	42	bevacizumab	Chemical	MESH:D000068258
30157683	50	61	bevacizumab	Chemical	MESH:D000068258
30157683	88	100	glioblastoma	Disease	MESH:D005909
30157683	140	143	CD4	Gene	920
30157683	171	178	ERC1671	CellLine	CVCL:2Y86
30157683	219	231	glioblastoma	Disease	MESH:D005909
30157683	233	236	GBM	Disease	MESH:D005909
30157683	279	284	tumor	Disease	MESH:D009369
30157683	302	307	tumor	Disease	MESH:D009369
30157683	338	345	patient	Species	9606
30157683	356	359	GBM	Disease	MESH:D005909
30157683	428	439	bevacizumab	Chemical	MESH:D000068258
30157683	446	454	patients	Species	9606
30157683	470	473	GBM	Disease	MESH:D005909
30157683	508	515	ERC1671	Chemical	-
30157683	625	641	cyclophosphamide	Chemical	MESH:D003520
30157683	647	658	bevacizumab	Chemical	MESH:D000068258
30157683	676	687	bevacizumab	Chemical	MESH:D000068258
30157683	738	746	patients	Species	9606
30157683	760	767	ERC1671	Chemical	-
30157683	773	784	bevacizumab	Chemical	MESH:D000068258
30157683	820	831	bevacizumab	Chemical	MESH:D000068258
30157683	877	880	CD4	Gene	920
30157683	927	934	ERC1671	Chemical	-
30157683	993	1000	ERC1671	Chemical	-
30157683	1008	1024	cyclophosphamide	Chemical	MESH:D003520
30157683	1028	1039	bevacizumab	Chemical	MESH:D000068258
30157683	1117	1125	toxicity	Disease	MESH:D064420
30157683	Cotreatment	MESH:D000068258	MESH:D003520
30157683	Negative_Correlation	MESH:D000068258	MESH:D005909
30157683	Negative_Correlation	MESH:D003520	MESH:D005909

